{"id":18261,"date":"2014-07-18T13:30:00","date_gmt":"2014-07-18T11:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/novartis-scommette-sui-dati-per-tagliare-i-costi-dei-farmaci\/"},"modified":"2014-07-18T13:30:00","modified_gmt":"2014-07-18T11:30:00","slug":"novartis-scommette-sui-dati-per-tagliare-i-costi-dei-farmaci","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-scommette-sui-dati-per-tagliare-i-costi-dei-farmaci\/","title":{"rendered":"Novartis bets on data to cut drug costs"},"content":{"rendered":"

 Bringing a new medicine to market is a huge undertaking. <\/span><\/strong>Between scientific research in the laboratory and the necessary clinical tests pass on average <\/span>11 years old<\/span><\/strong> <\/span>and investments are consequently exorbitant, to the point that only large multinationals can afford the risk and have the ability to raise capital.<\/span><\/p>\n

The Swiss drug giant Novartis<\/a><\/span><\/strong>, in our country at the center of a complex story concerning the<\/span>antitrust<\/span><\/b><\/a><\/span>, <\/span><\/span>the Ministry of Health and the National Health System<\/span><\/b><\/a><\/span>, has chosen the path of technology.<\/p>\n

<\/span><\/p>\n

During the Innovating for Patients event at the end of June organized at the company's Basel headquarters, Novartis Pharma's general manager of development Tim Wright showed a series of data for which a new molecule, at the time of commercialization, has added costs for a total of 4.6 billion dollars (3.4 billion euros). And one billion dollars of these costs derive from the failure of the molecules in the so-called phase 3 of the development, which is one of the last steps before the definitive approval by the authorities that govern the pharmaceutical market.<\/span> Portare sul mercato un nuovo medicinale è un’impresa enorme. Tra ricerca scientifica in laboratorio e i necessari test clinici per passano mediamente 11 anni e gli investimenti sono, di conseguenza, esorbitanti, al punto che solamente grosse multinazionali possono permettersi il rischio e hanno capacità di raccogliere il capitale. Il gigante svizzero del farmaco Novartis, nel nostro Paese …<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-18261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18261"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}